Preeclampsia Therapeutics Market Size, Share & Industry Analysis, By Preeclampsia Type (Mild Preeclampsia, Severe Preeclampsia), By Drug Class (Antihypertensive Agents, Anticonvulsants, Antioxidants, Others) and Regional Forecast, 2024-2032
KEY MARKET INSIGHTS
According to the National Institutes of Health (NIH), in 2016, an estimated 5.0-8.0% of pregnant women were affected by preeclampsia globally. The condition of preeclampsia occurs when a pregnant woman suffers from high blood pressure. The condition occurs after 20th week of pregnancy. There are two types of preeclampsia, mild preeclampsia, and severe preeclampsia.
Certain factors such as genetic disorders, blood vessels problems, autoimmune disorders, and weak immune system cause condition of preeclampsia. Preeclampsia shows symptoms such as sudden gain or loss of weight, high amount of protein in urine, high blood pressure, and abdominal pain. Preeclampsia is responsible for increased prevalence of premature births. According to preeclampsia foundation, globally, an estimated 20.0% of premature births are caused due to preeclampsia each year.
To gain extensive insights into the market, Request for Customization
Global preeclampsia therapeutics market growth is prominently being driven by the growing prevalence of preeclampsia. According to National Centre for Biotechnology Information (NCBI), preeclampsia is one of the prominent leading cause for maternal and fetal mortality.
Moreover, rise in risk factors for condition of preeclampsia such as obesity, diabetes, high blood pressure and increasing prevalence of genetic disorders projects growth in prevalence of preeclampsia, which will eventually increase the demand for preeclampsia therapeutics during forecast period. However, certain side effects of drugs for preeclampsia such as headache, nausea, and somnolence, also lack of healthcare infrastructure in emerging nations are restraining factors for growth of the global preeclampsia therapeutics market.
However, certain side effects of drugs for preeclampsia such as headache, nausea, and somnolence, also lack of healthcare infrastructure in emerging nations are restraining factors for growth of the global preeclampsia therapeutics market.
Key Players Covered
The major companies covered in the global preeclampsia therapeutics market report include Sera Prognostics, Inc., DRG INSTRUMENTS GMBH, F. Hoffmann-La Roche Ltd., PerkinElmer Inc., AMAG Pharmaceuticals, A1M Pharma AB, LFB S.A.,VG Life sciences, Inc., Pluristem Therapeutics Inc., and others.
Segmentation
ATTRIBUTE | DETAILS |
By Preeclampsia Type |
|
By Drug Class |
|
By Geography |
|
As per the current preeclampsia therapeutics market trends, antihypertensive agents among drug class segment is expected to hold a higher share of the market as it is highly prescribed drug type for the treatment of preeclampsia.
Key Insights
- Prevalence of preeclampsia for key countries
- Pipeline Analysis
- Reimbursement scenario for key countries
- Key mergers and acquisitions
Regional Analysis
The global preeclampsia therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to dominate the global preeclampsia therapeutics market during the forecast period owing to the rise in prevalence of preeclampsia. According to Preeclampsia Foundation, the rate of preeclampsia grew by an estimated 25.0% during past two decades in the U.S. alone. In Europe, rise in certain risk factors such as obesity, high blood pressure, and diabetes can lead to increase in prevalence of preeclampsia, which offers high opportunity for growth of the Europe preeclampsia therapeutics market. Asia Pacific and Middle East & Africa hold huge potential for growth of the global preeclampsia therapeutics market owing rapidly growing prevalence of preeclampsia.
Preeclampsia Therapeutics Industry Developments
- In April 2019, NHS announced proposed plan to launch an advanced blood test which can speed up the diagnosis of preeclampsia. The new test enables the authority to boost the treatment program for preeclampsia.
- In January 2017, Sera Prognostics signed a strategic agreement with Laboratory Corporation of America Holdings with an aim to expand its preeclampsia treatment product portfolio among extended geographical regions.
- Ongoing
- 2023
- 2019-2022
Personalize this Research
- Granular Research on Specified Regions or Segments
- Companies Profiled based on User Requirement
- Broader Insights Pertaining to a Specific Segment or Region
- Breaking Down Competitive Landscape as per Your Requirement
- Other Specific Requirement on Customization
Healthcare Clients
